Literature DB >> 24266815

Biomarkers to guide therapy or surveillance for prostate cancer.

Deborah Citrin1, Kathryn Hudak, Kevin A Camphausen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24266815      PMCID： PMC6342274          DOI： 10.2217/bmm.13.123

Source DB:  PubMed          Journal:  Biomark Med        ISSN： 1752-0363            Impact factor:   2.851


× No keyword cloud information.
  15 in total

1.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Authors:  Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone
Journal:  Lancet Oncol       Date:  2011-03       Impact factor: 41.316

2.  SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.

Authors:  Ming Yang; Wanling Xie; Elahe Mostaghel; Mari Nakabayashi; Lillian Werner; Tong Sun; Mark Pomerantz; Matthew Freedman; Robert Ross; Meredith Regan; Nima Sharifi; William Douglas Figg; Steven Balk; Myles Brown; Mary-Ellen Taplin; William K Oh; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

Review 3.  Prognostic determinants in prostate cancer.

Authors:  Neil E Martin; Lorelei A Mucci; Massimo Loda; Ronald A Depinho
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

4.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

5.  Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy.

Authors:  Barry S Rosenstein
Journal:  Pharmacogenomics       Date:  2011-02       Impact factor: 2.533

6.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

Authors:  M J Bussemakers; A van Bokhoven; G W Verhaegh; F P Smit; H F Karthaus; J A Schalken; F M Debruyne; N Ru; W B Isaacs
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

7.  The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.

Authors:  Michael W Kattan; Shahrokh F Shariat; Ben Andrews; Kuichun Zhu; Eduardo Canto; Kazumasa Matsumoto; Masatoshi Muramoto; Peter T Scardino; Makoto Ohori; Thomas M Wheeler; Kevin M Slawin
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

8.  Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.

Authors:  Ryan J Burri; Richard G Stock; Jamie A Cesaretti; David P Atencio; Sheila Peters; Christopher A Peters; Grace Fan; Nelson N Stone; Harry Ostrer; Barry S Rosenstein
Journal:  Radiat Res       Date:  2008-07       Impact factor: 2.841

9.  Contemporary risk profile of prostate cancer in the United States.

Authors:  Yu-Hsuan Shao; Kitaw Demissie; Weichung Shih; Amit R Mehta; Mark N Stein; Calpurnyia B Roberts; Robert S Dipaola; Grace L Lu-Yao
Journal:  J Natl Cancer Inst       Date:  2009-08-27       Impact factor: 13.506

Review 10.  Tissue biomarkers for prostate cancer radiation therapy.

Authors:  P T Tran; R K Hales; J Zeng; K Aziz; T Salih; R P Gajula; S Chettiar; N Gandhi; A T Wild; R Kumar; J M Herman; D Y Song; T L DeWeese
Journal:  Curr Mol Med       Date:  2012-07-01       Impact factor: 2.222
View more
  1 in total

1.  Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells.

Authors:  Varinder Jeet; Gregor Tevz; Melanie Lehman; Brett Hollier; Colleen Nelson
Journal:  Endocr Relat Cancer       Date:  2014-06-30       Impact factor: 5.678
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.